Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod

被引：0
|
作者：
Keenan, A. [1 ]
Gandhi, K. [1 ]
Le, H. H. [1 ]
Turkoz, I. [1 ]
Guo, S. [2 ]
Liao, W.
Pelligra, C. G. [3 ]
机构：
[1] Janssen Pharmaceut, Titusville, NJ USA
[2] Evidera, Waltham, MA USA
[3] Evidera, Bogota, Colombia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P085
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [41] The benefits of fingolimod in multiple sclerosis patients experiencing persistent disease activity despite previous treatment with disease-modifying therapies: results from the phase III TRANSFORMS study and its extension
    Cohen, J.
    Francis, G.
    Meinel, M.
    Eckert, B.
    JOURNAL OF NEUROLOGY, 2011, 258 : 258 - 258
  • [42] Disease activity, interferon-β-1b therapy and neuropsychological assessment in 50 relapsing-remitting multiple sclerosis patients:: preliminary results of a 2-year ongoing study
    Morra, VB
    Florio, C
    Scarano, V
    Vivo, R
    Lanzillo, R
    Muto, M
    Pristner, A
    Coppola, G
    Salvatore, E
    Pagano, A
    Schiavone, V
    Quarantelli, M
    Orefice, G
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S123 - S123
  • [43] Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results
    Gold, J.
    Marta, M. Calado
    Meier, U. C.
    Christensen, T.
    Miller, D.
    Altmann, D.
    Holden, D.
    Bianchi, L.
    Adiutori, R.
    MacManus, D.
    Yousry, T.
    Schmierer, K.
    Turner, B.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 188 - 189
  • [44] Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy
    Weinstock-Guttman, Bianca
    Bermel, Robert
    Csoboth, Csilla
    Cutter, Gary
    Freedman, Mark
    Leist, Thomas
    Ma, Xiaoye
    Musch, Bruno
    Reder, Anthony
    Stankiewicz, James
    Wolinsky, Jerry
    NEUROLOGY, 2020, 94 (15)
  • [45] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results)
    Fox, E. J.
    Bass, A. D.
    Aldridge, J.
    Evans, E.
    Lebson, L. A.
    Robertson, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 700 - 701
  • [46] Treatment effectiveness in relapsing remitting multiple sclerosis patients treated for 5 years with fingolimod in clinical practice: interim results from the observational study PANGAEA
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    Ettle, B.
    Schulze-Topphoff, U.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 286 - 287
  • [47] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [48] Effectiveness and safety of fingolimod in Spanish relapsing-remitting multiple sclerosis patients in clinical practice (Fingoview study): subanalysis of patients previously treated with first line injectable disease-modifying treatment
    Mallada, J.
    Meca-Lallana, J.
    Mart-Nez, M.
    Marzo, E.
    Duran, C.
    Ayuso, T.
    Barrero, F.
    Meca-Lallana, V.
    Martinez-Yelamos, S.
    Moreno, M. J.
    Salutregui, I.
    Ricart, J.
    Garcia, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 861 - 862
  • [49] Effectiveness and safety of fingolimod in Spanish Relapsing-Remitting Multiple Sclerosis patients in clinical practice (Fingoview study): Subanalysis of patients previously treated with first line injectable disease-modifying treatment
    Martinez, Marisa
    Barrero, Francisco
    Marzo, Eugenia
    Mallada Frechin, Javier Jose
    Meca-Lallana, Virginia
    Duran Herrera, Carmen
    Ayuso, Teresa
    Meca-Lallana, Jose
    Martinez Yelamos, Sergio
    Moreno Jimenez, Maria Jose
    Santos, Daniel
    Javier Ricart, Francisco
    Garcia, Eli
    NEUROLOGY, 2018, 90
  • [50] A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial
    Ziemssen, Tjalf
    Bajenaru, Ovidiu A.
    Carra, Adriana
    de Klippel, Nina
    de Sa, Joao C.
    Edland, Astrid
    Frederiksen, Jette L.
    Heinzlef, Olivier
    Karageorgiou, Klimentini E.
    Lander Delgado, Rafael H.
    Landtblom, Anne-Marie
    Macias Islas, Miguel A.
    Tubridy, Niall
    Gilgun-Sherki, Yossi
    JOURNAL OF NEUROLOGY, 2014, 261 (11) : 2101 - 2111
12345